The current state of HIV therapy

Formulary

Volumn 48, Issue 7, 2013, Pages 213-223

  Benzer, Jessica A ^a   Riley, Ted K ^a   Lee, Jean C ^a  

^a St Mary's Mercy Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; COBICISTAT PLUS ELVITEGRAVIR PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ETRAVIRINE; FOSAMPRENAVIR; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; INDINAVIR; INTEGRASE INHIBITOR; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RALTEGRAVIR; RILPIVIRINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; UNINDEXED DRUG; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL THERAPY; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CONFORMATIONAL TRANSITION; DIET RESTRICTION; DISEASE COURSE; DNA REPLICATION; DRUG METABOLISM; DYSLIPIDEMIA; GASTROINTESTINAL SYMPTOM; HEPATOMEGALY; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; INFECTION; KIDNEY CLEARANCE; KIDNEY DISEASE; LACTIC ACIDOSIS; LIFE EXPECTANCY; LIPODYSTROPHY; LIVER DISEASE; LIVER TOXICITY; MALIGNANT NEOPLASTIC DISEASE; MEDICATION COMPLIANCE; MENTAL DISEASE; NEUROLOGIC DISEASE; NEUROLOGICAL COMPLICATION; OPPORTUNISTIC INFECTION; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PREVALENCE; RASH; REVIEW; STEVENS JOHNSON SYNDROME; UNITED STATES; VIRION; VIRUS ENVELOPE; VIRUS LOAD;

EID: 84884526776     PISSN: 1082801X     EISSN: 19381166     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Kaiser Family Foundation. US Global Health Policy. Fact sheet: the Global HIV / AIDS Epidemic. December 2012. Available at: http://kaiserfamilyfoundation. fles. wordpress. com/2013/01/3030-17.pdf. Accessed June 15, 2013.
2. Kaiser Family Foundation. Fact sheet: the HIV/AIDS epidemic in the United States. HIV/AIDS Policy. March 2013. Available at: http://www. kff. org/hivaids/upload/3029-14.pdf. Accessed June 15, 2013.
3. CDC. National Center for HIV/AIDS, Viral Hepatitis, STD & TB Prevention. Division of HIV/AIDS Prevention. Trends in annual rates of death due to the 9 leading causes among persons 25-44 years old, United States, 1987-2009. Available at: http://www. cdc. gov/hiv/pdf/statistics_surveillance_statistics_ slides_HIV_mortality.pdf. May 2012. Accessed February 23, 2013.
4. FDA. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at: http://www. aidsinfo. nih. gov/ContentFi les/ AdultandAdolescentGL.pdf. Accessed Dec 9, 2012.
5. Lima VD, Harrigan R, Murray M, et al. Differential impact of adherence on long-term treatment response among naive HIV-infected individuals. AIDS. 2008;22:2371-2380.
6. Kakuda TN. Human immunodefciency virus infection. In: Talbert RL et al, eds. Pharmacotherapy: A Pathophysiologic Approach. 8th ed. New York: McGraw-Hill; 2011:2169-2190.
7. Viread (tenofovir disoproxil fumarate) [package insert]. Foster City, CA: Gilead Sciences, Inc.; November 2012.
8. Viramune (nevirapine) [package Insert]. Ridgefeld, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; November 2012.
9. Mills A, Antinori A, Clotet B, et al, on behalf of the ECHO and THRIVE study groups. Neurological and psychiatric tolerability of rilpivirine (TMC278) vs. efavirenz in treatment-naïve, HIV-1-infected patients at 48 weeks. HIV Med. 2013 Jan 9. doi: 10. 1111/ hiv. 12012 [Epub ahead of print].
10. Emmelkamp JM, Rockstroh JK. CCR5 antagonists: comparison of effcacy, side effects, pharmacokinetics and interactions-review of the literature. Eur J Med Res. 2007;12:409-417.
11. Selzentry (maraviroc) [package insert]. Research Triangle Park, NC: ViiV Healthcare; February 2013.
12. Ayoub A, Alston S, Goodrich J, et al. Hepatic safety and tolerability in the maraviroc clinical development program. AIDS. 2010;24:2743-2750.
13. Walmsley S, Campo R, Goodrich J, et al. Low risk of malignancy with maraviroc in treatment-experienced and treatment-naïve patients across the maraviroc clinical development program. From the XVIII International AIDS Conference, July 18-23, 2010; Vienna, Austria. Abstract TUPE0157.
14. Fuzeon (enfuvirtide) [package insert]. South San Francisco, CA: Genentech, Inc. and Trimeris, Inc.; 2012.
15. Lu J, Deeks SG, Hoh R, et al. Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: results of a clonal analysis. J Acquir Immune Defc Syndr. 2006;43:60-64.
16. Isentress (raltegravir) [package insert]. Whitehouse Station, NJ: Merck & Co Inc.; 2012.
17. Lee FJ, Amin J, Bloch M, Pett S, Marriott D, Carr A. Skeletal muscle toxicity associated with raltegravir-based combination antiretroviral therapy in HIV-infected adults. J Acquir Immune Defc Syndr. 2013;62:525-533.
18. Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate) [package insert]. Foster City, CA: Gilead Sciences, Inc.; August 2012.
19. FDA. Antiretroviral drugs used in the treatment of HIV Infection. Available at: http:// www. fda. gov/ForConsumers/byAudience/ ForPatientAdvocates/HIVandAIDSActivities/ ucm118915. htm. Accessed February 10, 2013.
20. Cohen CJ, Molina JM, Cahn P, et al, on behalf of the ECHO and THRIVE Study Groups. Effcacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naïve HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials. J Acquir Immune Defc Syndr. 2012;60:33-42.
21. Edurant (rilpivirine) [package insert]. Titusville, NJ: Janssen Therapeutics; December 2012.
22. Complera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) [package insert]. Foster City, CA: Gilead Sciences, Inc.; January 2013.
23. Rimsky L, Vingerhoets J, Van Eygen V, et al. Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis. J Acquir Immune Defc Syndr. 2012;59:39-46.
24. Lenz JCC, Rockstroh JK. S/GSK1439572, a new integrase inhibitor for the treatment of HIV: promises and challenges. Expert Opin Investig Drugs. 2011;20:537-548.
25. Koteff J, Borland J, Chen S, et al. A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in health subjects. Br J Clin Pharmacol. 2013;75:990-996.
26. Walmsley S, Antela A, Clumeck N, et al. Dolutegravir (DTG: S/GSK 1349572) + abacavir/lamivudine once daily statistically superior to tenofovir/emtricitabine/efavirenz: 48-week results-SINGLE (ING114467). From the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 9-12, 2012, San Francisco, CA. Abstract H-556b.
27. Raff F, Rachlis A, Stellbrink HJ, et al, on behalf of the SPRING-2 study group. Oncedaily dolutegravir versus raltegravir in antiretroviral-naïve adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet. 2013;381:735-743.
28. Nichols G, Mills A, Grossberg R, et al. Antiviral activity of dolutegravir in subjects with failure on an integrase inhibitor-based regimen: week 24 phase 3 results from VIKING-3. From the 11th International Congress on Drug Therapy in HIV Infection, November 11-15, 2012; Glasgow, United Kingdom. Abstract O232.
29. Pozniak A, Mingrone H, Shuldyakov A, et al. Dolutegravir (DTG) versus raltegravir (RAL) in ART-experienced, integrase-naïve subjects: 24-week interim results from SAILING (ING111762). From the 20th Conference on Retroviruses and Opportunistic Infections, March 3-6, 2013; Atlanta, GA. Abstract 179LB.
30. Anderson M, Gilmartin J, Robberechts M, et al. Safety and antiviral activity of MK-1439, a novel NNRTI, in treatment-naïve HIV+ patients. From the 20th Conference on Retroviruses and Opportunistic Infections, March 3-6, 2013; Atlanta, GA. Abstract 100.
31. Anderson MS, Gilmartin J, Cilissen C, et al. Safety, tolerability, and pharmacokinetics of single and multiple doses of MK-1439, a novel HIV non-nucleoside reverse transcriptase inhibitor in healthy subjects. From the 20th Conference on Retroviruses and Opportunistic Infections, March 3-6, 2013; Atlanta, GA. Abstract J-163.
32. Ruane P, DeJesus E, Berger D, et al. GS-7340 25 mg and 40 mg demonstrate superior effcacy to tenofovir 300 mg in a 10-day monotherapy study of HIV-1+ patients. From the 19th Conference on Retroviruses and Opportunistic Infections, March 5-8, 2012; Seattle, WA. Abstract 103.
33. Birkus G, Bam RA, Frey CR, et al. Intracellular activation pathways for GS-7340 and the effect of antiviral protease inhibitors. From the 19th Conference on Retroviruses and Opportunistic Infections, March 5-8, 2012; Seattle, WA. Poster 577.
34. Zolopa A, Ortiz R, Sax P, et al. Comparative study of tenofovir alafenamide vs. tenofovir disoproxil fumarate, each with elvitegravir, cobicistat, and emtricitabine, for HIV treatment. From the 20th Conference on Retroviruses and Opportunistic Infections, March 3-6, 2013; Atlanta, GA. Paper 99LB.
35. Gilead Sciences. Gilead's once-daily novel prodrug for the treatment of HIV meets 24-week primary objective in phase 2 study. Press release, Oct. 31, 2012. Available at: http://investors. gilead. com/phoenix. zhtml?c=69964&p=irolnewsArticle& ID=1752101&highlight=. Accessed March 25, 2013.
36. Truvada (emtricitabine/tenofovir disoproxil fumarate) [package insert]. Foster City, CA: Gilead Sciences, Inc.; July 2012.
37. FDA. Truvada approved to reduce the risk of sexually transmitted HIV in people who are not infected with the virus. Nov. 7, 2012. Available at: http://www. fda. gov/ForConsumers/ ByAudience/ForPatientAdvocates/ HIVandAIDSAct ivities/ucm312264. htm. Accessed March 1, 2013.
38. Grant RM, Lama JR, Anderson P, et al, for the iPrEx Study Team. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587-2599.
39. Baeten JM, Donnell D, Ndase D, et al, for the Partners PrEP Study Team. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367:399-410.
40. Thigpen MC, Kebaabetswe PM, Paxton LA, et al; TDF2 Study Group. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367:423-434.
41. Van Damme L, Corneli A, Ahmed K, et al; FEM-PrEP Study Group. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367:411-422.
42. U. S. Centers for Disease Control and Prevention. Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. MMWR Morb Mortal Wkly Rep. 2011;60:65-68.
43. U. S. Centers for Disease Control and Prevention. Interim guidance for clinicians considering the use of preexposure prophylaxis for the prevention of HIV infection in heterosexually active adults. MMWR. 2012;61:586-589.
44. OraSure Technologies Inc. OraQuick Educational Guide for Healthcare Professionals. Available at: http://www. oraquick. com/ assets/base/oraquickful l /pdf /8453_02_ MultiPager_L.pdf. Accessed June 15, 2013.
45. OraQuick In Home HIV Test [package insert]. Bethlehem, PA: OraSure Technologies, Inc; June 2012.